Last week, the FDA granted breakthrough designation to Pfizer’s (NYSE:PFE) experimental advanced breast cancer drug PD-0332991 or Palbociclib. [1] The FDA grants breakthrough status to drugs that are likely to demonstrate substantial improvement over ...
[Published Trefis - Apr 18 2013]